Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25480681 | 0.88 | ALDH1A1 (0.37) | MEN1ALDH1A1POLBCYP2C19KMT2A | |
| SCHEMBL23188090 | 0.82 | ATM (0.37) | MEN1POLBKMT2ATSHRATM | |
| SCHEMBL23188086 | 0.75 | KMT2A (0.33) | MEN1ALDH1A1POLBCYP2C19KMT2A | |
| SCHEMBL23136072 | 0.71 | TSHR (0.49) | MEN1ALDH1A1POLBCYP2C19KMT2A | |
| SCHEMBL23135917 | 0.68 | TSHR (0.49) | MEN1ALDH1A1POLBCYP2C19KMT2A | |
| SCHEMBL26278834 | 0.67 | TSHR (0.39) | MEN1POLBKMT2ATSHRATM | |
| SCHEMBL4993792 | 0.66 | FOLH1 (0.37) | MEN1ALDH1A1KMT2AHPGDTSHR | |
| SCHEMBL19429955 | 0.65 | ALDH1A1 (0.37) | MEN1ALDH1A1POLBCYP2C19KMT2A | |
| SCHEMBL22624454 | 0.64 | TSHR (0.43) | MEN1ALDH1A1POLBCYP2C19KMT2A | |
| SCHEMBL2736123 | 0.63 | ACACB (0.38) | ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141212-A1 | SUBSTITUTED BENZENECARBOXAMIDES AS IL-17A MODULATORS | DICE ALPHA, INC. | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141212-A1 | SUBSTITUTED BENZENECARBOXAMIDES AS IL-17A MODULATORS | IL17A, IL2, IL23R | MEN1 4876/4885ALDH1A1 372/4885POLB 1703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.